Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of two daily wear silicon hydrogel contact lens

Conditions: Myopia

Summary: the purpose of this study is to demonstrate that the visco (olifilcon a) soft contact lens could be prescribed as a supportive care for myopic persons.

this randomized controlled study will involve at least 50 evaluable subjects divided evenly among 5 study sites in taiwan. each study site will enroll 12 subjects at least. the ration of evaluable test subjects to control subjects will be 2 to 1. subjects who have normal ocular health and conform to a set of standard criteria will wear one of the study lenses on two eyes and follow up for 3 months (90 days). lenses will be assigned to subject according to a predetermined randomized order. it is necessary to remove contact lenses every day and replace after 30 days. any unscheduled visit will be allowed when there is a medication necessary. the data for slit lamp findings, symptoms/problems/complaints, keratometry (k) reading, refractive changes (absolute value), visual acuity data, average wear time (awt), discontinuations, and lens replacement will be collected to claim that the visco soft contact lens is as safe and effective as biofinity (comfilcon a) soft contact lens (coopervision).

Eligibility criteria:
inclusion criteria: * subject should have normal eyes and use no ocular medications * subject with -1.00 to -10.00 d myopia, less than -1.25 d astigmatism * va correctable to 20/25 or better. * willing to comply with all study procedures and be available for the duration of the study. * provide signed and dated informed consent form. exclusion criteria: * subjects have history of allergies that would contraindicate solution use and/or "normal" contact lens wear. * cornea sensitivity low, high myopes, keratoconus, dry eye with schirmer test \< 5mm/5min or other physical condition that would contraindicate contact lens wear. * subjects have other active ocular or systemic disease that would contraindicate contact lens wear. * subjects have medications that would contraindicate contact lens wear. * females who are pregnant, breastfeeding, birth control pill taken or who intended to become pregnant over the course of the study. * current drug or alcohol use or dependence that would interfere with adherence to study requirements. * individuals participating in other clinical studies.
classification of adenocarcinoma of the esophagogastric junction

Conditions: Oesophagus Cancer; Barrett Esophagus; Siewert Type I Adenocarcinoma of Esophagogastric Junction; Siewert Type II Adenocarcinoma of Esophagogastric Junction; Siewert Type III Adenocarcinoma of Esophagogastric Junction

Summary: the siewert classification of oesophageal cancer is the standard approach in anatomically subdividing cancer of the lower oesohagus.

retrospective review of tumour biology, pathological staging and outcomes in the participants based on siewert classification. the investigators to scrutinise this scoring system to evaluate if it is indeed appropriate.

Eligibility criteria:
inclusion criteria: * all patients exclusion criteria: -
presence or absence of blood in the gi lumen

Conditions: Upper GI Bleeding

Summary: bleedings in the upper digestive tract are common. usually, laboratory and clinical parameters are considered to establish a suspicion for a bleeding in the digestive tract and to estimate urgency of the situation. if these parameters suggest the presence of a bleeding in the digestive tract, endoscopies are often performed to further investigate a patient's status. the above-mentioned laboratory and clinical parameters are sometimes not specific enough to reliably identify a bleeding in the upper digestive tract. the hemopill acute is capsule device, that has a built in sensor that detects blood in the upper digestive tract. this information is valuable for the medical personnel and complements the information that is obtained from other laboratory or clinical tests

the purpose of the study was to access safety and accuracy of hemopill and its receiver. patients scheduled for endoscopy on the basis of suspected ugib are generally eligible for inclusion into the trial. after patient screening, information and obtaining informed consent, a patient is enrolled into the trial. shortly before the scheduled endoscopy is performed, the patient ingests a hemopill acute. endoscopy is performed as scheduled. blood within the gi lumen is identified if present and pictures are taken. pathologies, if found, are treated as per clinical standard. the hemopill acute measurement regarding presence or absence of blood in the gi lumen is compared to observations made during endoscopy.

Eligibility criteria:
inclusion criteria: * patient is scheduled for endoscopy due to suspicion of ugib based on clinical and / or laboratory findings * signed informed consent * age ≥ 18 years * willingness and ability to participate in the study procedure exclusion criteria: * contraindications to the use of the hemopill acute, such as: * known gastrointestinal obstruction, stricture, fistula, or diverticula * dysphagia or other swallowing disorders * pregnancy * incapacity to provide informed consent * in patients with cardiac pacemakers and other implanted medical devices
ultrasound guided steroids injection versus prp for shoulder pain relief

Conditions: Shoulder Pain

Summary: comparison between effects of ultrasound guided platelet rich plasma injection versus steroids injection for pain relief in cases of partial rotator cuff tears

the effect of injection of platelet rich plasma will be compared with effects of steroids injection according to pain relief effects,, side effects ,, healing ability ,, recurrence in both groups. 30 patient in each group will be included

Eligibility criteria:
inclusion criteria: 1. patients with positive tests for rotator cuff pain 2. patients with positive radiological (us or mri) findings of partial rotator cuff tear exclusion criteria: 1. patient refusal 2. age less than 20 years. 3. infection at injection site. 4. prior surgery on the shoulder joint area. 5. presence of other associated pathology in the shoulder joint 6. patients using antiplatelet drugs (aspirin). 7. contraindications to the use of platelet concentrate 8. contraindications to the steroids injection
assessing of artificial intelligence-based software platform for diabetic retinopathy screening

Conditions: Diabetic Retinopathy

Summary: to examine the potential for the detection of diabetic retinopathy (dr) using the artificial intelligence (ai)-based software platform retina-ai.

operator took fundus images with a non-mydriatic fundus camera as per the retina-ai checkeye imaging protocol (an optic disc centered image and a fovea centered image for each eye).thereafter, operator uploaded fundus images in the ai system for processing by the neural network.

Eligibility criteria:
inclusion criteria: 1. documented diagnosis of diabetes mellitus by definition. 2. understanding of the study and willingness and ability to sign informed consent 3. patient age 18 or above 4. diagnostic for diabetes: 4a) type 1 diabetes of a lest 5 years of evolution; or 4b) type 2 diabetes exclusion criteria: -1. patients under 18 years of age; 2. failure to give informed consent; 3. presence of retinal diseases - acquired disease: age-related macular degeneration (amd), occlusion of retinal vessels (orv), etc.; birth defects: coloboma of choroid or optic nerve disc, etc.; hereditary diseases: retinitis pigmentosa, angioid streaks of the retina, etc. 4. a patient who has already undergone treatment (surgery, laser, etc.) for any disease of the retina: age-related macular degeneration (amd), retinal vascular occlusion (arv), etc. these patients should be excluded or allocated to a separate group.

Keywords: diabetic retinopathy fundus photo nonmydriatic camera artificail intelligence checkeye fundus image fundus photography
pbp versus halsted's model: the provesa trial

Conditions: Educational Problems

Summary: this randomized controlled trial aims to compare the effectiveness of halsted's apprenticeship approach to training with the pbp approach for teaching the robotic suturing of a vua on a chicken model.

in a prospective, randomized and blinded study robotic naïve (urology (n = 12), surgery (n = 12) and gynecology (n = 12)) residents (n = 36) from the ku leuven and university of gent residency training programs will be randomized (in equal discipline numbers) to traditional halstedian apprenticeship type training or proficiency based progression (pbp) training to learn to perform a vesico-urethral anastomosis (vua) on a chicken model. both groups will receive the same e-learning (on how to perform the vua on the chicken model) and skills laboratory robotic training curriculum. the pbp trained group will however be required to demonstrate quantitively defined proficiency benchmarks for training progression (i.e., from e-learning to the skills lab). the pbp group will also have a defined benchmark to demonstrate before training is deemed completed. the traditional trained group will train in the same skills laboratory for a case-matched period of time as the pbp group, with the same level of supervising faculty proctors and using the same training resources but with no proficiency benchmarks or metric-based feedback. both groups will be required to perform a vua on the chicken model before skills training proper and at the end of training. investigators will be trained in pairs to assess vua performance from a pre-defined set of explicitly defined binary metric events reliably (inter-rater reliability \> 0.8). they will also be blinded as to the identity of the trainee performing the procedure, how they were trained (i.e., group) and procedure order. h1 it is hypothesized that implementation of pbp training in teaching the robotic suturing of vua leads to better surgical training outcomes (i.e., lower number of performance errors) when compared to halsted's method.

Eligibility criteria:
inclusion criteria: * recently accepted, first or second year residents gynecology and obstetrics (n=12), urology (n=12) and general surgery (n=12). novice in robotic surgery. exclusion criteria: * any robotic experience

Keywords: surgery robotics training vesico-urethral anastomosis proficiency based progression basic skills training
the effects of soy dietary fiber in adults with diarrhea predominant irritable bowel syndrome

Conditions: Diarrhea Predominant Irritable Bowel Syndrome

Summary: the investigators will evaluate the efficacy of soy dietary fiber in adults with diarrhea predominant irritable bowel syndrome.


Eligibility criteria:
inclusion criteria: * willing to consent/undergo necessary procedures * between the age of 19 and 75 years * diarrhea predominant irritable bowel syndrome (satisfied with rome ii criteria) exclusion criteria: * uncontrolled hypertension (blood pressure \> 170/100 mmhg) * uncontrolled diabetes mellitus (fbs \> 180 mg/dl) * malignancy, cerebrovascular disease, cardiovascular disease * history of abdominal surgery except appendectomy and hernia repair * inflammatory bowel disease * clinically or laboratory-confirmed gastroenteritis * the use of motility drug or dietary fiber supplement in 2 weeks * allergy to soy fiber * serum cr \> 2 x upper normal limit * ast or alt \> 2 x upper normal limit * pregnancy, lactating woman
dataglove to measure joint stiffness in patients with arthritis

Conditions: Arthritis, Rheumatoid

Summary: this study will investigate if an electronic dataglove can be used to measure joint stiffness in patients with rheumatoid arthritis.

we will use a dataglove to record joint movements in a small number of patients with rheumatoid arthritis. the aim of the study is to find out if changes in dynamic movements measured by the glove will correlate with symptoms of joint stiffness in the hands of patients with rheumatoid arthritis.

Eligibility criteria:
inclusion criteria: * male and female patients aged 18 to 80 * diagnosis of rheumatoid arthritis * patients who have significant pain and stiffness in their hands * correct hand size to achieve a good fit to the dataglove * able to follow instructions for use of dataglove/computer exclusion criteria: * severe pain in the right hand * severe swelling in the right hand (rated as such by the investigator) * severe permanent deformity or loss of function in the fingers of the right hand * broken or infected skin in the right hand * known to have been mrsa positive currently or in the past * unable to don and doff the disposable lining glove and the dataglove without significant discomfort * poor fit for the disposable lining glove or the dataglove * history of latex allergy

Keywords: arthritis stiffness range of movement goniometry digital dataglove outcome
a study to investigate the effect of itraconazole and rifampin on pharmacokinetics (pk) of vemurafenib at steady state

Conditions: Metastatic Melanoma, BRAF V600 Mutation Positive

Summary: this is a two-part, phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the pk of vemurafenib following multiple 960 milligrams (mg) twice daily (bid) dosing in adult participants with unresectable stage iiic or stage iv metastatic melanoma positive for the braf v600 mutation, or other malignant tumor types that harbor a v600-activating mutation of braf where the participant has no acceptable standard treatment options.


Eligibility criteria:
inclusion criteria: * participants with age greater than or equal to (\>=) 18 years with either unresectable stage iiic or stage iv metastatic melanoma positive for the braf v600 mutation, or other malignant tumor types that harbor a v600-activating mutation of braf * eastern cooperative oncology group performance status 0 to 2 * life expectancy \>=12 weeks * adequate hematologic and end organ function obtained within 2 weeks prior to first dose of study drug * female participants of childbearing potential and male participants with partners of childbearing potential must agree to always use two effective methods of contraception including at least one method with a failure rate of \<1% per year during the course of the study and for at least 6 months after completion of study treatment * negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential * absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule exclusion criteria: * prior treatment with vemurafenib or other braf inhibitor within 42 days of study day 1 of period a * allergy or hypersensitivity to components of the vemurafenib formulation * experimental therapy within 4 weeks prior to first dose of study drug treatment on study day 1 of period a * major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug treatment on study day 1 of period a, or anticipation of the need for major surgery during study treatment * prior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy) within 28 days (6 weeks for nitrosoureas or mitomycin c, and 14 days for hormonal therapy or kinase inhibitors) before the first dose of study treatment on study day 1 of period a.
ω3 lcpufas for healthy growth and development of infants and young children in southwest ethiopia

Conditions: Child Malnutrition

Summary: new approaches are needed to prevent growth failure in children from low- and middle-income countries (lmic). to date, nutrition intervention studies have focused on micronutrient and energy content of complementary foods and have yielded only small to moderate effects on growth and development. there appears to be a missing link that mediates and reduces the expected beneficial effect. child populations in lmic show an asymptomatic environmental enteropathy that is characterized by a reduced size of the small intestinal villi, decreased gut integrity and a chronic inflammatory response in the gut. results from studies in industrialized countries suggest that ω3 long-chain polyunsaturated fatty acids (ω3 lcpufas) improve immune response and gut integrity. these reported beneficial effects could result in even more important physiological implications for children from lmic and will ultimately contribute to their healthy growth and development. the hypothesis of the ome³jim study is that an increased intake of ω3 lcpufas through complementary foods and human milk has an effect on infant growth and development in a context of high malnutrition rates and low ω3 lcpufas intake. this study will identify whether intake by either or both mother and infant is more effective. the specific objectives of the ome³jim study are: 1. to test the effect of supplementing infants with an ω3 lcpufas fortified food supplement on infant growth, morbidity, nutritional status and development; 2. to test the effect of supplementing lactating mothers with an ω3 lcpufas oil capsule on infant growth, nutritional status and development; 3. to test the combined effect (dose response) of supplementing ω3 lcpufas to lactating mothers and infant on infant growth, morbidity, nutritional status and development: 4. to test the effect of ω3 lcpufas supplementation on ω3 lcpufa status in infants and human milk.


Eligibility criteria:
inclusion criteria: * singleton infants * 6-12 months old * not suffering from acute malnutrition (wasting): whz \> -2 , no edema * infants currently being breastfed * anticipated local residence for the study duration * not planning to leave the study area for more than 1 month exclusion criteria: * current supplement use or medical treatment of infant and/or mother * infants developing severe anemia (\<70 g/l) or edema are referred to the nearby health institution for evaluation and treatment, and are omitted from the trial * presence of congenital abnormalities

Keywords: malnutrition.
a phase i study of hrs2300 or combined with shr-1316 or shr-1701 or trametinib or almonertinib in patients with advanced malignancies

Conditions: Advanced Malignancies

Summary: the study is being conducted to evaluate the safety and tolerability of hrs2300 and combined with shr-1316 or shr-1701 or trametinib or almonertinib.to determine the maximum tolerated dose (mtd) and recommended dose (rp2d) for hrs2300 monotherapy and combination therapy.


Eligibility criteria:
inclusion criteria: 1. aged 18-75 years old，male or female; 2. patients with pathologically confirmed advanced solid tumors who did not respond to standard treatment, did not tolerate standard treatment, or were determined by the investigator to be unsuitable for standard treatment; 3. ecog ps score of 0-1; 4. life expectancy of ≥3 months; 5. able and willing to provide a written informed consent. exclusion criteria: 1. receiving chemotherapy, targeted therapy, immunotherapy, radical radiotherapy or surgical treatment for less than 4 weeks before study therapy (excluding tyrosine kinase inhibitors or other small molecule targeted drugs \< 2 weeks); four weeks prior to the start of study treatment (patients who have entered the follow-up period measured by the time of last use of the experimental drug or device) were enrolled in another clinical study; 2. drugs that affect the activity of metabolic enzyme cyp3a have been used in the past, and the eluting period from the end time to the first administration in this study is within 5 half-lives; 3. patients with active tb within 1 year prior to the start of drug therapy or with a history of active tb infection more than 1 year prior to the start of drug therapy without proper treatment were studied; 4. patients with other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator.
lubiprostone in patients with multiple sclerosis associated constipation

Conditions: Multiple Sclerosis; Constipation

Summary: the purpose of the study is to assess how safe and effective the drug lubiprostone is in people with multiple sclerosis (ms)and moderate to severe ms-associated constipation. lubiprostone is approved by the fda for the treatment of two common types of constipation in adults, chronic idiopathic constipation and irritable bowel syndrome.

multiple sclerosis (ms) is a disorder of the body's immune system that affects the central nervous system. normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the bowel. in people with ms, the covering around the nerve fibers deteriorates, causing nerve impulses to be slowed or stopped. as a result, patients with ms may experiences constipation.

Eligibility criteria:
inclusion criteria: * multiple sclerosis * chronic constipation defined as \< 3 spontaneous bowel movements per week by history and confirmed by diary during the 14 day washout period. * women of child-bearing potential must agree to use adequate birth control. exclusion criteria: * history of other clinically significant medical or psychiatric disorders or suicidal ideation. * subjects who have a suspicion of a mechanical bowel obstruction by clinical evaluation prior to dosing that include nausea, vomiting, abdominal pain or distention. * subjects with a positive urine pregnancy test prior to dosing. * medication changes within one month prior to visit one. * corticosteroid use within 2 months prior to visit one. * age\<18. * known intolerance to lubiprostone. * inability to perform any required study procedures.

Keywords: multiple sclerosis constipation multiple sclerosis associated constipation